On August 27, 2025, Sonoma Pharmaceuticals, Inc. conducted its annual meeting where stockholders elected Dr. Jay Birnbaum as a Class II director, approved executive compensation, ratified the independent auditor, and authorized a meeting adjournment for additional proxies. The total shares entitled to vote were 1,642,765, with 718,469 shares present or represented.